Literature DB >> 20937530

Progressive multifocal leukoencephalopathy.

Robert Weissert1.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a disease of the central nervous system (CNS) with destructive infection of oligodendrocytes by JC virus. PML belongs to the opportunistic infections. It is observed in patients with HIV infection, lymphoid malignancies, after organ- and stem cell transplantations and more recently in the context of modern immune-therapies with monoclonal antibodies (mAb) like natalizumab, rituximab, infliximab and efalizumab. The natural course of PML is fatal within months. More recently, the Immune Reconstitution Inflammatory Syndrome (IRIS) has been observed in patients with HIV infection treated with combination antiretroviral therapy (cART) as well as patients in whom the PML-inducing immune therapy has been terminated. In PML-IRIS the immune system contributes to the elimination of JC virus from the CNS and if PML-IRIS emerges, PML can be survived but can lead as well to catastrophic outcomes with brain herniation and death. Therefore the management of IRIS requires special knowledge in JC virus biology and patient care. JC virus infection is possibly involved in a variety of additional neurological conditions and cancer. Much will be learned within the next years that could change our view on the understanding of JC virus and human disease.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20937530     DOI: 10.1016/j.jneuroim.2010.09.021

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

1.  A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.

Authors:  Nobuo Sanjo; Yurie Nose; Yukiko Shishido-Hara; Saneyuki Mizutani; Yoshiki Sekijima; Hitoshi Aizawa; Toru Tanizawa; Takanori Yokota
Journal:  J Neurol       Date:  2018-12-03       Impact factor: 4.849

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

3.  Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy.

Authors:  Letizia Tirelli; Francesca Rosini; Alessandra Rufa; Guido Garosi; Alfonso Cerase; Antonio Federico; Andrea De Luca
Journal:  Neurol Sci       Date:  2017-04-18       Impact factor: 3.307

Review 4.  Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.

Authors:  Emanuele D'Amico; Aurora Zanghì; Carmela Leone; Hayrettin Tumani; Francesco Patti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

Review 5.  Monoclonal antibody therapy-associated neurological disorders.

Authors:  Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

Review 6.  Pain, Headache, and Other Non-motor Symptoms in Myasthenia Gravis.

Authors:  Olivia Tong; Leslie Delfiner; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

Review 7.  The immune pathogenesis of multiple sclerosis.

Authors:  Robert Weissert
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-10       Impact factor: 4.147

8.  Progressive multifocal leukoencephalopathy: a rare cause of cerebellar edema and atypical mass effect. A case report.

Authors:  Chris Ojeda; Rachid Assina; Maureen Barry; Ada Baisre; Chirag Gandhi
Journal:  Neuroradiol J       Date:  2014-06-17

9.  JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics.

Authors:  Colleen L Mayberry; Christian D S Nelson; Melissa S Maginnis
Journal:  Curr Clin Microbiol Rep       Date:  2017-08-01

Review 10.  Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.

Authors:  Sheng Chen; Jun Hu; Liang Xu; Dixon Brandon; Jun Yu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.